Summary
In order to investigate the role of the PTEN expression in carcinogenesis and development of endometrial carcinoma and clarify whether and how PTEN and PI3K/Akt pathway relate to endometrial carcinoma, the expression of PTEN and phospho-Akt was detected by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) methods and Western-blot from 24 cases of endometrial carcinoma, 10 cases of endometrial atypical hyperplasia, 10 cases of endometrial hyperplasia, and 10 cases of normal endometrium. SP immunohistochemical methods were used to measure levels of PTEN protein expression in following 5 study groups: 31 cases of endometrium in proliferative phase, 30 cases of endometrium in secretory phase, 71 cases of endometrial hyperplasia, 25 cases of atypical hyperplasia and 73 cases of endometrial carcinoma. Immunostaining score of PTEN was 3.39±0.15 in proliferative phase, 1.90±0.21 in secretory phase, 3.34±0.29 in endometrial hyperplasia, 0.62±0.11 in atypical hyperplasia, and 0.74±0.19 in endometrial carcinoma, respectively. PTEN mRNA relative value in normal endometrium, endometrial hyperplasia, endometrial atypical hyperplasia, and endometrial carcinoma was 2.45±0.51, 2.32±0.32, 0.46±0.11, and 0.35±0.13 respectively. The expression levels of PTEN mRNA and protein in patients with endometrial carcinoma and atypical hyperplasia were significantly lower than in those of proliferative phase and with endometrial hyperplasia. The level of PTEN expression in patients with endometrial carcinoma was significantly related to tissue type (P<0.005), differentiation (P<0.05) and clinical stage (P<0.05), but not to depth of myometrium invasion (P>0.05). Western blot analysis revealed that Phospho-Akt level in PTEN negative cases was significantly higher, and there was a negative correlation between PTEN and phospho-Akt (r=−0.8973, P<0.0001). It was suggested that loss of PTEN expression was an early event in endometrial tumorigenesis. The phosphorylation of Akt induced by the loss of PTEN took part in the tumorigenesis and development of endometrial carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boruban MC, Altundag K, Kilic GS, et al. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev, 2008,17(2):133–138
Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer, 2006, 6(5): 360–368
Llobet D, Pallarés J, Yeramian A, et al. Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutical view points. J Clin Pathol, 2008, Oct 31 [Epub ahead of print]
Li L, Ross AH. Why is PTEN an important tumor suppressor? J Cell Biochem, 2007,102(6):1368–1374
Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res, 2006,12(20):5932–5935
Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst, 2000,92:924–931
Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PI3K and PTEN genes in endometrial carcinoma. Cancer Res, 2005,65(23):10 669–10 673
Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol, 2006,37(11):1465–1472
Dubrovska A, Kim S, Salamone RJ, et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci U S A, 2008, Dec 30. [Epub ahead of print]
Rychahou PG, Kang J, Gulhati P, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci U S A, 2008, 105(51):20 315–20 320
Albitar L, Pickett G, Morgan M, et al. Models representing type I and type II human endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol, 2007,106(1):52–64
Inaba F, Kawamata H, Teramoto T, et al. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma. Oncol Rep, 2005,13(1):17–24
Guzeloglu-Kayisli O, Kayisli UA, Al-Rejaal R, et al. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab, 2003,88(10):5017–5026
Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol, 2006, 24(29):4783–4791
Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology, 2007, 39(1):72–87
Gründker C, Günthert AR, Emons G, et al. Hormonal heterogeneity of endometrial cancer. Adv Exp Med Biol, 2008,630:166–188
Carnero A, Blanco-Aparicio C. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets, 2008,8(3):187–198
Hartmann W, Digon-Söntgerath B, Koch A, et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res, 2006,12(10): 3019–3027
Author information
Authors and Affiliations
Additional information
This project was supported by the grants from 973 National Great Foundation Research Program of China (No. 2002CB 513100) and National Natural Sciences Foundation of China (No. 30600667).
Rights and permissions
About this article
Cite this article
Gao, Q., Ye, F., Xia, X. et al. Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 29, 59–63 (2009). https://doi.org/10.1007/s11596-009-0112-6
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-009-0112-6